⚖
Compare Funds
See how two funds stack up side by side, real returns, risk, cost and portfolio overlap.
VS
Key Metrics Comparison
| Metric | Tata India Pharma & Healthcare Fund - Growth - Direct Plan | HDFC Pharma and Healthcare Fund - Growth - Direct Plan |
|---|---|---|
| Snapshot | ||
| AMC | Tata MF | HDFC MF |
| Category | Equity - Sectoral Fund - Pharma & Health Care | Equity - Sectoral Fund - Pharma & Health Care |
| NAV | ₹37.54 (29 Oct 2026) | ₹21.95 (30 Oct 2026) |
| Rating | ★★★★★ | ★★★★★ |
| Benchmark | BSE Health Care - TRI | BSE Health Care - TRI |
| Fund Manager | Rajat Srivastava | Nikhil Mathur |
| Inception | 28 Dec 2015 | 04 Oct 2023 |
| Returns | ||
| 1Y | 3.37% | 22.64% |
| 3Y | 19.08% | 30.41% |
| 5Y | 14.78% | — |
| Since Inception | 12.97% | 29.15% |
| Risk | ||
| 14.24 | 14.07 | |
| 0.69 | 0.59 | |
| 0.87 | 1.59 | |
| 12.04 | 21.67 | |
| 1.81 | 3.48 | |
| -9.86% | -9.23% | |
| Costs | ||
| Expense Ratio | 1.07% | 1.03% |
| Exit Load | 0.25% on or before 30D | 1% on or before 30D, Nil after 30D |
| Min SIP | ₹100 | ₹100 |
| Min Lumpsum | ₹5,000 | ₹100 |
| Lock-in | None | None |
Min SIP is reported per fund, not per plan, every plan of a fund shares the same figure.
Portfolio Overlap
Tata MF60%
HDFC MF60%
40.0%Only 40.0% of holdings by weight are common between Tata MF and HDFC MF, based on each fund's top 20 disclosed holdings, not the full portfolio.
Common holdingTata MFHDFC MF
Sun Pharmaceutical Industries Ltd.7.99%8.28%
Divi's Laboratories Ltd.5.68%9.39%
Cipla Ltd.4.22%4.15%
Apollo Hospitals Enterprise Ltd.4.36%3.69%
Torrent Pharmaceuticals Ltd.3.76%3.65%
Max Healthcare Institute Ltd.3.71%3.61%
Dr. Reddy's Laboratories Ltd.4.65%3.19%
Lupin Ltd.3.14%3.55%
Anthem Biosciences Ltd.2.57%3.17%
Alkem Laboratories Ltd.2.36%4.64%
Category context: Equity vs Equity. Open the full Screener →